Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Cancer Res. 2016 Dec 28;15(3):328–339. doi: 10.1158/1541-7786.MCR-16-0257-T

Figure 2.

Figure 2

DAP and oxaliplatin stabilize p53 in a dose-dependent manner in resistant 2780CP/Cl-16 and 2780CP/Cl-24 cells. A2780 (A), 2780CP/Cl-16 (B) and 2780CP/Cl-24 (C) cells were exposed to increasing concentrations of cisplatin, DAP or oxaliplatin for 24 hours. Cells were then collected and p53 expression levels determined by Western blot analysis. The p53 and β-actin signals in the immunoblots were quantified by densitometry, the ratios of p53/β-actin were then plotted against drug concentration.